Press Release - Company Data

Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer
Posted 2014-07-11 00:03NAI Editing
Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition.

Transition Therapeutics Announces Closing of Private Placement Equity Financing
Posted 2014-06-23 11:04NAI Editing
announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N.

Transition Therapeutics Announces Closing of Private Placement Equity Financing
Posted 2014-06-23 00:10NAI Editing
announced that it has closed its previously announced private placement through which 3,195,487 units of the Company were purchased by Jack W. Schuler, Larry N.

Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8 Million in Equity Financing
Posted 2014-06-06 00:11NAI Editing
announced that Jack W. Schuler, Larry N.

Transition Therapeutics Announces Development Update
Posted 2014-04-06 23:33NAI Editing
provided an update on the development of its drug candidates and plans for future growth.

Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$21.7 Million in Equity Financing
Posted 2013-08-01 23:49NAI Editing
announced that Jack W. Schuler, Larry N.

Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly
Posted 2013-06-16 23:40NAI Editing
announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial Results
Posted 2013-05-07 06:45NAI Editing
a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and nine month periods ended March 3

Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes Drug Candidate TT-401
Posted 2013-04-30 00:36NAI Editing
announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects.

Transition Therapeutics Announces Second Quarter Fiscal 2013 Financial Results
Posted 2013-02-07 07:08NAI Editing
a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December